HomeInsightsResults

Jenburkt Pharmaceuticals Ltd Quarterly Result

Jenburkt Pharmaceuticals Ltd Quarterly Result

stocks purchased

₹ 0.3 Cr

Volume Transacted

(Nov 26, 2024)

stocks purchased

2.1 K

Stocks Traded

(Nov 26, 2024)

Last Updated on: Nov 27, 2024

Image

Jenburkt Pharmaceuticals Ltd

NSE: JENBURKTPHARMA

Net Profit

₹ 9.6

Last updated on: Nov 27, 2024

Key Highlights

  • The revenue of Jenburkt Pharmaceuticals Ltd for the Sep '24 is ₹ 43.07 crore as compare to the Jun '24 revenue of ₹ 33.94 crore. This represent the growth of 26.900417%.
  • The ebitda of Jenburkt Pharmaceuticals Ltd for the Sep '24 is ₹ 13.28 crore as compare to the Jun '24 ebitda of ₹ 10.7 crore. This represent the growth of 24.11215%.
  • The net profit of Jenburkt Pharmaceuticals Ltd for the Sep '24 is ₹ 9.6 crore as compare to the Jun '24 net profit of ₹ 7.42 crore. This represent the growth of 29.380058%.

Results Analysis

Market Price of Jenburkt Pharmaceuticals Ltd

1M

1Y

3Y

5Y

Monitoring Jenburkt Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
26 Nov 20241247.8
25 Nov 20241228.2
22 Nov 20241162.35
21 Nov 20241129.1
19 Nov 20241198.1
18 Nov 20241197.5
14 Nov 20241197.1
13 Nov 20241123.45
12 Nov 20241187.5
11 Nov 20241218.4

Historical Revenue of Jenburkt Pharmaceuticals Ltd

No data available

* All values are in crore

Historical EBITDA of Jenburkt Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Jenburkt Pharmaceuticals Ltd

No data available

* All values are in crore

Jenburkt Pharmaceuticals Ltd News Hub

News

Jenburkt Pharmaceuticals to announce Quarterly Result

Jenburkt Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5...

Read more

29 Oct 202415:24

News

Jenburkt Pharmaceuticals to declare Quarterly Result

Jenburkt Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 2...

Read more

19 Jul 202410:24

News

Jenburkt Pharmaceuticals to conduct AGM

Jenburkt Pharmaceuticals announced that the 39th Annual General Meeting (AGM) of the compa...

Read more

24 Jun 202409:36

News

Board of Jenburkt Pharmaceuticals recommends final dividend

Jenburkt Pharmaceuticals announced that the Board of Directors of the Company at its meeti...

Read more

29 May 202410:57

News

Jenburkt Pharmaceuticals schedules board meeting

Jenburkt Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 2...

Read more

21 May 202415:36

News

Jenburkt Pharmaceuticals to announce Quarterly Result

Jenburkt Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 6...

Read more

20 Jan 202412:45

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQ's For Jenburkt Pharmaceuticals Ltd Quarterly Result

What is the EPS of Jenburkt Pharmaceuticals Ltd stock?

The Earnings Per Share (EPS) of Jenburkt Pharmaceuticals Ltd is 68.66. An EPS is the amount of net income attributed to each share of a common stock.

How is Jenburkt Pharmaceuticals Ltd EPS calculated?

The EPS of Jenburkt Pharmaceuticals Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Jenburkt Pharmaceuticals Ltd report its EPS?

Jenburkt Pharmaceuticals Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Jenburkt Pharmaceuticals Ltd EPS?

Factors that influence the EPS of Jenburkt Pharmaceuticals Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Jenburkt Pharmaceuticals Ltd EPS growth indicate future performance?

Yes, consistent growth in Jenburkt Pharmaceuticals Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*